相关实验视频

Updated: Jun 24, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

在急性淋巴细胞白血病中药理学PIP4K2抑制剂的效力和疗效

Keli Lima¹, Frederico Lisboa Nogueira², Marcella Cipelli³

¹Laboratory of Medical Investigation in Pathogenesis and Targeted Therapy in Onco-Immuno-Hematology (LIM-31), Department of Internal Medicine, Hematology Division, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil; Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.

European journal of pharmacology

|June 8, 2024

概括

在急性淋巴细胞白血病 (ALL) 中,酸-4-酸5-激酶2型 (PIP4K2) 基因表达有所变化. PIP4K2抑制剂THZ-P1-2有效地降低了ALL细胞活力和诱导细胞死亡.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
生物化学生物化学

背景情况:

急性淋巴细胞白血病 (ALL) 呈现PIP4K2基因的差异表达.
在所有骨髓中,PIP4K2A水平升高,而PIP4K2B水平降低.
在ALL的临床结果与PIP4K2基因表达水平没有很强的相关性.

研究的目的:

研究PIP4K2抑制剂在ALL中的治疗潜力.
在ALL细胞模型中评估THZ-P1-2,a131和CC260的疗效.
阐明ALL中PIP4K2抑制的分子机制.

主要方法:

在ALL细胞模型中测试三种PIP4K2抑制剂 (THZ-P1-2,a131,CC260).
评估细胞活力,新陈代谢,细胞死亡和线粒体损伤.
分析自流和PI3K/AKT/mTOR信号通路.

主要成果:

与a131和CC260.0相比,THZ-P1-2显示出更高的疗效.
THZ-P1-2显著降低了细胞活力和新陈代谢,诱导细胞死亡和线粒体损伤.
THZ-P1-2独特地破坏了自流并抑制了PI3K/AKT/mTOR通路.

结论:

PIP4K2A可能在ALL的发病过程中发挥作用.
THZ-P1-2显示了对ALL治疗的治疗前景.
THZ-P1-2表现出不同的作用机制,包括对自和PI3K/AKT/mTOR通路的影响.

关键词:

急性淋巴细胞白血病 (Acute Lymphoblastic Leukemia) 是一种急性淋巴细胞白血病.抗瘤药剂是一种抗瘤药剂.药物开发药物开发酸氨基醇5-酸盐4-酶2型

更多相关视频

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...